Sen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons Capital to Advance SJP-001 Clinical Trial with Novotech
Sen-Jam Pharmaceutical, a leader in innovative solutions targeting inflammation and metabolic health, proudly announces a financial and strategic investment from 5 Horizons Capital. Horizon, as the lead investor for the Phase 2 clinical trial of SJP-001, Sen-Jam's flagship therapeutic, is paving the way for innovation in collaboration with Novotech, a global full-service clinical Contract Research […]